Prostate Cancer
Conditions
Brief summary
The study is to examine a moderate hypofractionation regimen of proton beam therapy for high risk or unfavorable intermediate risk prostate cancer. The prostate and seminal vesicles are treated with 6750 centigray (RBE) in 25 fractions (i.e. 270 centigray/fraction), while the regional pelvic nodes receive 4500 centigray (RBE) in 25 fractions (i.e. 180 centigray/fraction) simultaneously. The overall treatment time is 5 weeks.
Detailed description
Proton beam therapy can provide a therapeutic gain by offering at least equivalent (or superior) tumor control while reducing the risk of radiation toxicity, in comparison with conventional photon-based external beam radiotherapy, given its dose-deposition characteristics. Currently the clinical target volume of proton beam for the treatment of prostate cancer has been mostly limited to the prostate and the seminal vesicles. There has been no study of proton beam therapy to treat both the primary tumor in the prostate and the regional pelvic nodes simultaneously using a moderate hypofractionation regimen. The study is a prospective, single-arm, clinical trial to evaluate a moderate hypofractionation regimen of proton beam therapy for high risk or unfavorable intermediate risk prostate cancer. The clinical target volumes of proton beam therapy include both the prostate/seminal vesicles and the regional pelvic nodes. The primary objective is to assess late grade ≥ 3 gastrointestinal (GI) and genitourinary (GU) toxicity. The secondary objectives are to evaluate late grade ≥ 2 GI and GU toxicity, acute grade ≥ 3 GI and GU toxicity, and disease-free survival including freedom from PSA (prostate specific antigen) relapse at 5 years. The study provides an avenue to examine the safety, efficacy, cost effectiveness, and convenience of a moderate hypofractionation regimen (5-week course) of proton beam therapy.
Interventions
RADIATIONHypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes
Sponsors
Mayo Clinic
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male; Age ≥ 18 years. * Histological confirmation of adenocarcinoma of the prostate within 6 months of study enrollment. * Clinical stage T1-2 N0 M0, Gleason Score 7, Prostate Specific Antigen (PSA) 20-100 ng/mL, or Clinical stage Any T N0 M0, Gleason Score 8-10, PSA ≤ 100 ng/mL, or Clinical stage T3-4 N0 M0, any Gleason Score, PSA ≤ 100 ng/mL, or Clinical stage T1-2 N0 M0, Gleason Score 4+3, PSA 10-20 ng/mL * Zubrod performance score (PS) ≤ 1 * Total bilirubin, aspartate aminotransferase, alkaline phosphatase, and serum creatinine: \< 2 x upper normal limit * Signed informed consent.
Exclusion criteria
* Any known nodal (N1) or distant metastasis (M1) * Previous androgen deprivation therapy lasting more than 6 months * History of inflammatory bowel disease * Presence of a hip prosthesis * Prior pelvic radiotherapy or prostatectomy * Prior or concurrent antineoplastic agents (chemotherapy) * Previous or concurrent malignancy other than non-melanoma skin cancer within 5 years of diagnosis of prostate cancer. * Inability to start the protocol treatment within 1 month after study enrollment. * Medical or psychiatric conditions that preclude informed decision-making or compliance with the protocol treatment or follow-up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Late Grade ≥ 3 Gastrointestinal (GI) and Genitourinary (GU) Toxicity of Interest, Using the CTCAE v4.0 | Between 3 months and 24 months post proton beam therapy | Toxicity will be defined as an adverse event possibly, probably, or definitely related to proton beam therapy. A late GI or GU toxicity will be defined as a GI or GU toxicity that occurs between 3 months and 2 years from the completion of proton beam therapy. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for late toxicity, with the exception of patients determined to be a major violation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Late Grade ≥ 2 GI and GU Toxicity of Interest, Using the CTCAE v4.0 | Between 3 months and 24 months post proton beam therapy | Toxicity will be defined as an adverse event possibly, probably, or definitely related to proton beam therapy. A late GI or GU toxicity will be defined as a GI or GU toxicity that occurs between 3 months and 2 years from the completion of proton beam therapy. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for late toxicity, with the exception of patients determined to be a major violation |
| Acute Grade ≥ 3 GI and GU Toxicity of Interest Within 3 Months Post Proton Beam Therapy, Using the CTCAE v4.0 | Within 3 months post proton beam therapy | Toxicity will be defined as an adverse event possibly, probably, or definitely related to proton beam therapy. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for late toxicity, with the exception of patients determined to be a major violation |
| Disease-free Survival Including Freedom From PSA Relapse at 5 Years Post Proton Beam Therapy | 5 years post proton beam therapy | Disease-free survival is defined as the time from registration until the time of the first occurrence of biochemical failure, local recurrence, regional recurrence, distant metastases, or death due to any cause. The distribution of disease-free survival will be estimated using the method of Kaplan-Meier. |
| Disease-specific Survival at 5 Years Post Proton Beam Therapy | 5 years post proton beam therapy | Disease-free survival is defined as the time from registration until the time of the first occurrence of biochemical failure, local recurrence, regional recurrence, distant metastases, or death due to any cause. The distribution of disease-free survival will be estimated using the method of Kaplan-Meier. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Hypofractionation Proton Beam Therapy Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes\>\>\>\>
\>\>\>\> Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes | 54 |
| Total | 54 |
Baseline characteristics
| Characteristic | Hypofractionation Proton Beam Therapy |
|---|---|
| Age, Continuous | 75.5 years |
| Baseline IPSS score 0-7 | 28 Participants |
| Baseline IPSS score 20-35 | 2 Participants |
| Baseline IPSS score 8-19 | 22 Participants |
| Baseline PSA, ng/mL | 10.7 ng/mL |
| BMI | 29.0 kg/m^2 |
| Duration of ADT (mo) | 18.1 months |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 51 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 3 Participants |
| Gleason score 6 | 4 Participants |
| Gleason score 7 | 17 Participants |
| Gleason score 8-10 | 33 Participants |
| History of prior TURP No | 49 Participants |
| History of prior TURP Yes | 5 Participants |
| Performance status (ECOG) ECOG score 0 | 47 Participants |
| Performance status (ECOG) ECOG score 1 | 7 Participants |
| Prostate volume (mL) | 41.1 mL |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 2 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 3 Participants |
| Race (NIH/OMB) White | 49 Participants |
| Risk High-risk | 52 Participants |
| Risk Unfavorable intermediate risk | 2 Participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 54 Participants |
| T stage T1-T2 | 23 Participants |
| T stage T3a | 21 Participants |
| T stage T3b | 10 Participants |
| T stage T4 | 0 Participants |
| Use of alpha-1 blocker No | 49 Participants |
| Use of alpha-1 blocker Yes | 5 Participants |
| Use of antiplatelet or anticoagulant medication No | 43 Participants |
| Use of antiplatelet or anticoagulant medication Yes | 11 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 55 |
| other Total, other adverse events | 55 / 55 |
| serious Total, serious adverse events | 0 / 55 |
Outcome results
Primary
Late Grade ≥ 3 Gastrointestinal (GI) and Genitourinary (GU) Toxicity of Interest, Using the CTCAE v4.0
Toxicity will be defined as an adverse event possibly, probably, or definitely related to proton beam therapy. A late GI or GU toxicity will be defined as a GI or GU toxicity that occurs between 3 months and 2 years from the completion of proton beam therapy. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for late toxicity, with the exception of patients determined to be a major violation.
Time frame: Between 3 months and 24 months post proton beam therapy
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Hypofractionation Proton Beam Therapy | Late Grade ≥ 3 Gastrointestinal (GI) and Genitourinary (GU) Toxicity of Interest, Using the CTCAE v4.0 | GI grade ≥ 3 | 1 Participants |
| Hypofractionation Proton Beam Therapy | Late Grade ≥ 3 Gastrointestinal (GI) and Genitourinary (GU) Toxicity of Interest, Using the CTCAE v4.0 | GU grade ≥ 3 | 0 Participants |
Secondary
Acute Grade ≥ 3 GI and GU Toxicity of Interest Within 3 Months Post Proton Beam Therapy, Using the CTCAE v4.0
Toxicity will be defined as an adverse event possibly, probably, or definitely related to proton beam therapy. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for late toxicity, with the exception of patients determined to be a major violation
Time frame: Within 3 months post proton beam therapy
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Hypofractionation Proton Beam Therapy | Acute Grade ≥ 3 GI and GU Toxicity of Interest Within 3 Months Post Proton Beam Therapy, Using the CTCAE v4.0 | GI grade ≥ 3 | 0 Participants |
| Hypofractionation Proton Beam Therapy | Acute Grade ≥ 3 GI and GU Toxicity of Interest Within 3 Months Post Proton Beam Therapy, Using the CTCAE v4.0 | GU grade ≥ 3 | 0 Participants |
Secondary
Disease-free Survival Including Freedom From PSA Relapse at 5 Years Post Proton Beam Therapy
Disease-free survival is defined as the time from registration until the time of the first occurrence of biochemical failure, local recurrence, regional recurrence, distant metastases, or death due to any cause. The distribution of disease-free survival will be estimated using the method of Kaplan-Meier.
Time frame: 5 years post proton beam therapy
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Hypofractionation Proton Beam Therapy | Disease-free Survival Including Freedom From PSA Relapse at 5 Years Post Proton Beam Therapy | 90 percentage of participants |
Secondary
Disease-specific Survival at 5 Years Post Proton Beam Therapy
Disease-free survival is defined as the time from registration until the time of the first occurrence of biochemical failure, local recurrence, regional recurrence, distant metastases, or death due to any cause. The distribution of disease-free survival will be estimated using the method of Kaplan-Meier.
Time frame: 5 years post proton beam therapy
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Hypofractionation Proton Beam Therapy | Disease-specific Survival at 5 Years Post Proton Beam Therapy | 89 percentage of participants |
Secondary
Late Grade ≥ 2 GI and GU Toxicity of Interest, Using the CTCAE v4.0
Toxicity will be defined as an adverse event possibly, probably, or definitely related to proton beam therapy. A late GI or GU toxicity will be defined as a GI or GU toxicity that occurs between 3 months and 2 years from the completion of proton beam therapy. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for late toxicity, with the exception of patients determined to be a major violation
Time frame: Between 3 months and 24 months post proton beam therapy
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Hypofractionation Proton Beam Therapy | Late Grade ≥ 2 GI and GU Toxicity of Interest, Using the CTCAE v4.0 | GI grade ≥ 2 | 6 Participants |
| Hypofractionation Proton Beam Therapy | Late Grade ≥ 2 GI and GU Toxicity of Interest, Using the CTCAE v4.0 | GU grade ≥ 2 | 19 Participants |